Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, Alberto Bedogni
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2018-09-01
coleção:	Dentistry Journal
Assuntos:	osteonecrosis of the jaw ONJ osteonecrosis jaw medication-related osteonecrosis of the jaw MRONJ multiple myeloma denosumab zoledronic acid
Acesso em linha:	http://www.mdpi.com/2304-6767/6/3/42
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!